Blog | Creyos | Cognitive Testing for Better Brain Health

The Growth of Value-Based Care in 2026

Written by Andrea Welsh, LPN, CHPC | Nov 17, 2026, 3:30:35 PM

Value-based care adoption in 2026 is uneven, and the organizations carrying financial risk face substantial exposure. Participation is still rising, while the share of payments under downside risk has held steady. In 2024, 28.7% of U.S. healthcare payments flowed through alternative payment models with downside risk, meaning organizations repay part of any spending above a benchmark. In 2026, 82.8% of Medicare Shared Savings Program accountable care organizations had moved into the program’s higher-risk levels.

Benchmarks, quality performance, and care plans all rest on what clinicians have assessed and documented. With more exposure, each gap in that record costs more. Undetected cognitive impairment is a common gap, with consequences for patients and for spending.

Article Highlights

The growth of value-based care in 2026

Medicare’s accountable care programs keep adding participants. The Medicare Shared Savings Program grew from 476 accountable care organizations in 2025 to 511 in 2026. Those ACOs serve 12.6 million people with Traditional Medicare, a 12.3% increase from 2025. Across all Centers for Medicare & Medicaid Services (CMS) accountable care initiatives, an estimated 14.3 million Medicare beneficiaries were in an ACO relationship in January 2026.

By contrast, the share of payments in value-based arrangements has barely moved. Across all lines of business, alternative payment models carried 44.9% of U.S. healthcare payments in 2024, compared with 45.2% in 2023. Over the same period, the share under downside risk held nearly flat, moving from 28.5% to 28.7%.

Much of the change is happening inside existing value-based care models. Some organizations are moving from upside-only shared savings, where they keep part of any savings and repay nothing, toward two-sided risk and capitation. Under full capitation, a fixed per-member payment places the full spending difference on the organization.

CMS policy points the same way. The CMS Innovation Center’s Long-term Enhanced ACO Design (LEAD) model launches in 2027, when ACO REACH concludes. CMS has also finalized Shared Savings Program changes intended to bring more ACOs into two-sided risk. For organizations already in these contracts, more revenue is now tied to performance against risk-adjusted benchmarks.

Why financial risk raises the cost of missing clinical information

Under two-sided risk, losses carry a defined price. In the Medicare Shared Savings Program, ACOs in two-sided tracks repay a share of spending above their benchmark, at a fixed 30% in the BASIC track’s two-sided levels and between 40% and 75% in the ENHANCED track. An ENHANCED ACO that fails to meet the quality performance standard repays at the full 75%. In the ENHANCED track, quality performance therefore shapes both the savings an organization can earn and the losses it absorbs.

Medicare Advantage payments and Shared Savings Program benchmarks are both risk-adjusted, so they depend on the clinical complexity recorded for each patient. For 2026, CMS calculates non-PACE Medicare Advantage risk scores entirely with the 2024 CMS-HCC model (V28), and Shared Savings Program benchmarks are also adjusted in part using CMS-HCC risk scores. A condition that clinicians haven’t recognized and documented is absent from the risk profile in both, and payments or benchmarks can understate the care the population needs.

The technology built for value-based care works from the same record. EHR adoption is nearly ubiquitous among office-based physicians, and analytics, risk stratification, and point-of-care tools surface what those records contain. Each depends on a clinician having assessed and documented the condition first.

For organizations carrying downside risk, each condition missing from the record carries a larger financial and clinical cost.

How undetected cognitive impairment affects care and healthcare spending

A care plan relies on the patient to understand it, remember it, and act on it between visits. Yet an estimated 92% of expected mild cognitive impairment (MCI) cases in the Medicare population went undiagnosed in 2015–2019 data. When impairment goes unrecognized, a missed refill or skipped follow-up can look like nonadherence. A systematic review of medication adherence in older adults with cognitive impairment identified barriers such as understanding new directions and fitting medications into a daily routine.

Undetected impairment is also associated with worse hospital outcomes. In a national study of 6,296 older adults with linked Medicare claims, people with undiagnosed dementia were discharged to a facility after 44.8% of hospitalizations, compared with 19.3% among those without dementia. They also had roughly twice the odds of a 30-day readmission compared with patients whose dementia had been diagnosed.

When it comes to costs, the pattern is also similar. Among 8,165 Medicare fee-for-service beneficiaries, cognitive impairment was associated with about $6,900 in additional annual healthcare costs for women and $7,300 for men, more than half of it inpatient, after accounting for comorbidities. For organizations carrying downside risk, that spending already sits within the attributed population, whether or not the record has documented it. These findings are observational associations, and any savings from screening depend on what follow-up care changes.

The Annual Wellness Visit as a detection point in primary care

Medicare gives primary care a defined point to look for cognitive impairment, in a visit beneficiaries can choose to attend. CMS requires clinicians to detect any cognitive impairment during initial and subsequent Annual Wellness Visits (AWVs), names changes in memory, judgment, decision-making, and medication adherence among the signs to look for, and permits the use of a brief cognitive test.

The screening method affects what gets found, and in a study cited in the Alzheimer’s Association’s AWV cognitive assessment recommendations, a brief structured tool correctly classified patients with dementia or MCI more often than spontaneous detection by their own primary care physicians (83% vs. 59%). Because the U.S. Preventive Services Task Force has found the evidence insufficient to assess routine screening of older adults without symptoms, how structured that detection should be remains an organizational decision.

A standardized assessment also gives the clinician a consistent result to interpret alongside the patient’s history. Clinical evaluation then determines what follows, whether that is monitoring, further workup, or a cognitive assessment and care planning visit (CPT 99483).

Evaluation can change care directly, through steps such as assessing function and reversible contributors, simplifying medications, involving a caregiver, and naming an owner who confirms follow-through. When that evaluation confirms dementia, documenting it with its stage carries into the risk scores described above, so they reflect the population’s actual complexity. The detection point serves the patient first, and accurate documentation follows from the clinical work.

Building a traceable route from detection to coordinated care

When a quality metric exposes a problem, the cause often sits in a handoff. Tracing a finding from where it entered the record to where it stopped moving shows who owned the next action and whether it happened, and a pattern that recurs across locations points to a workflow problem that needs an organization-wide fix.

One large multi-state health network built that route into its standard workflow using Creyos. Population health staff use EHR registries to identify eligible patients, which this organization defined as adults 50 and older with no prior dementia diagnosis, and the system sends a brief digital screener through the patient portal before the visit. Results flow back into the record, so the clinician has a scored report at the appointment and follows a defined pathway for monitoring, further workup, or referral.

Building a similar route rests on a few decisions made before rollout:

  • Population. Which patients to prioritize first, and what triggers an assessment.
  • Ownership. Who orders the assessment, reviews the result, and owns follow-up at each site.
  • Capacity. Administration can fit into existing workflows, but reviewing results, arranging evaluation, and coordinating care require planned clinical and care management time.
  • Success measures. Assessment completion, completed evaluations, care-plan changes, time from a positive result to evaluation, and change in the quality and utilization measures the contract already tracks, against baseline data, a comparison group where feasible, and total clinical and technology costs.

Cognitive impairment affects medication management, follow-up, and care-plan adherence across a risk-bearing population, often before it appears in the record. A traceable route from detection to coordinated care brings that need into view, shows whether follow-up changes care, and gives leadership the evidence to decide whether to scale.

Written by Andrea Welsh, LPN, CHPC

Andrea Welsh, LPN, CHPC, is a nurse and medical writer with clinical experience in geriatric, primary care, and behavioral health settings. She has managed quality and compliance programs supporting value-based care in community health centers and holds the Certified in Healthcare Privacy Compliance (CHPC) credential. She speaks at healthcare conferences on data literacy and clinical documentation.

How we keep this article accurate
We review our content regularly to ensure it is up to date.
Share
 
Published
November 17, 2026
Reviewed by
Dr. Anthony Zizza
Chief Medical Officer, Element Care and Clinical Advisor at Creyos